Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-20
2005-09-20
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S250000, C514S058000
Reexamination Certificate
active
06946464
ABSTRACT:
The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.
REFERENCES:
patent: 3862149 (1975-01-01), Cotrel et al.
patent: 4220646 (1980-09-01), Cotrel et al.
patent: 5786357 (1998-07-01), Young et al.
patent: 6339086 (2002-01-01), Jerussi et al.
patent: 6339089 (2002-01-01), Nakashima et al.
patent: 6458791 (2002-10-01), Jerussi et al.
patent: 6506753 (2003-01-01), Jerussi et al.
patent: 2003/0166657 (2003-09-01), Jerussi et al.
patent: 93/10787 (1993-06-01), None
patent: 93/10788 (1993-06-01), None
Hempel et al, Enantioselective determination of zopiclone . . . , Journal of Chromatography B, 1996, vol. 675, pp. 139-146.
Mannaert et al., Semi-preparative chiral resolution of zopiclone . . . , Journal of Pharmaceutical and Biomedical Analysis, 1996, vol. 14, pp. 1367-1370.
Fernandez et al., Clinical Pharmacokinetics of zopiclone., Clinical Pharmacokinetics, (abstract only), 1995, vol. 29(6), pp. 431-441.
Gasior et al., Acute and Chronic effects of the synthetic neuroactive . . . , Neuropharmacology, (abstract only), 2000, vol. 39(7), pp. 1184-1196.
Brun, J.P.,Pharm. Biochem. Behav. 29:831-832 (1988).
Castello, R.A., and Mattocks, A.M.,J. Phram. Sci. 51(2):106-108 (1962).
Goa, K.L. and Heel, R.C.,Drugs, (Abstr.) 32:48-65 (1986).
Goodman&Gilman's The Pharmacological Basis of therapeutics, Hardman, J.G., et al., eds. p. 142, 365 (9thed., 1996).
Handbookof Pharmaceutical Excipients, 2nded., Wade and Willer eds., pp. 257-259 (1994).
Julou, L., et al.,Pharmacol. Biochem. Behav. 23:653-659 (1985).
Meldrum, B.S.,Brit, J. Clin. Phar. 27(suppl. 1):3S-11S (1989).
Olofson, R.A. and Martz, T.J.,J. Org. Chem., 49:2081 (1984).
Sato, Katsuhiko, et al.,Pharmacologic Studies of Central Actions of Zopiclone. Influence on Brain Monoamines in Rats Under Stressful Condition, (Abstr.),Tokyo Ika Daigaku Zasshi, 1985 vol. 43(1), pp. 45-51.
Turner, W., et al., A.,J. Med. Chem. 20(8):1065-1068 (1977).
Verma, A. and Synder, S.H.,Ann. Rev. Pharmacol. Toxicol. 29:307-22 (1989).
Bakale Roger A.
Hong Yaping
Jerussi Thomas P.
McConville Fran A.
Rubin Paul D.
Jones Day
Kim Vickie
Sepracor Inc.
LandOfFree
Methods of treating and preventing a convulsive state does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating and preventing a convulsive state, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating and preventing a convulsive state will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3378014